WorldPingSTAT
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
WorldPingWhen it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.
This is a short WorldPing brief. The full report was published by STAT.
Read the full report at STAT